Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Prepaid Assets (2019 - 2025)

Historic Prepaid Assets for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $8.5 million.

  • Allogene Therapeutics' Prepaid Assets fell 3366.27% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year decrease of 3366.27%. This contributed to the annual value of $10.9 million for FY2024, which is 472.26% up from last year.
  • As of Q3 2025, Allogene Therapeutics' Prepaid Assets stood at $8.5 million, which was down 3366.27% from $9.5 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Prepaid Assets ranged from a high of $22.5 million in Q2 2022 and a low of $7.9 million during Q3 2023
  • Moreover, its 5-year median value for Prepaid Assets was $11.5 million (2025), whereas its average is $13.2 million.
  • Per our database at Business Quant, Allogene Therapeutics' Prepaid Assets tumbled by 5500.98% in 2023 and then soared by 6166.81% in 2024.
  • Over the past 5 years, Allogene Therapeutics' Prepaid Assets (Quarter) stood at $14.0 million in 2021, then decreased by 17.95% to $11.5 million in 2022, then decreased by 9.44% to $10.4 million in 2023, then rose by 4.72% to $10.9 million in 2024, then dropped by 21.86% to $8.5 million in 2025.
  • Its last three reported values are $8.5 million in Q3 2025, $9.5 million for Q2 2025, and $11.5 million during Q1 2025.